10-Q: InspireMD Q3 Revenue Jumps 39% on US CGuard Prime Launch

InspireMD reports significant revenue growth in Q3 2025 driven by the US commercial launch of its CGuard Prime carotid stent system, despite increased net losses and ongoing liquidity concerns.

Summary

• Revenue for the three months ended September 30, 2025, increased by 39.4% to $2.523 million, up from $1.810 million in the prior year period.
• Gross profit for Q3 2025 more than doubled to $864,000, compared to $414,000 in Q3 2024, with gross margin improving to 34.2% from 22.9%.
• Net loss for Q3 2025 increased by 61.1% to $12.708 million, up from $7.890 million in Q3 2024, primarily due to a significant increase in operating expenses.
• For the nine months ended September 30, 2025, revenue grew by 15.2% to $5.830 million, and net loss increased by 62.2% to $37.025 million.
• The company successfully launched its CGuard Prime Carotid Stent System in the United States in July 2025, following FDA PMA approval in June 2025.
• InspireMD raised approximately $40.1 million in gross proceeds from a private placement offering in July 2025 and $16.9 million net from Series I warrant exercises.
• Despite increased cash and equity, management expresses substantial doubt about the company's ability to continue as a going concern for at least the next 12 months due to recurring losses and negative operating cash flows.

Sentiment

Score: 4

Explanation: While the company achieved significant product approvals and revenue growth, the substantial increase in net loss, negative operating cash flow, and explicit 'going concern' warning indicate significant financial challenges and high operational risk, tempering the positive commercial developments.

Positives

• Revenue for the three months ended September 30, 2025, increased by $713,000, or 39.4%, to $2,523,000, driven by the US commercial launch of CGuard Prime and international growth.
• Gross profit for Q3 2025 increased by $450,000, or 108.7%, to $864,000, with gross margin improving to 34.2% from 22.9% due to higher unit profit from direct US sales.
• The CGuard Prime Carotid Stent System received CE Mark approval under the European Medical Device Regulation on June 13, 2025.
• The U.S. Food and Drug Administration (FDA) granted premarket application (PMA) approval for the CGuard Prime Carotid Stent System on June 23, 2025.
• The official commercial launch of the CGuard Prime carotid stent system in the United States commenced in July 2025.
• The company secured approximately $40.1 million in gross proceeds from a private placement offering that closed on August 1, 2025.
• Exercise of Series I Warrants generated approximately $16.9 million in net proceeds during June and July 2025.
• Cash and cash equivalents significantly increased to $63,403,000 as of September 30, 2025, from $18,916,000 at December 31, 2024.
• Positive one-year follow-up results from the C-GUARDIANS trial showed a 30-day DSMI and ipsilateral stroke rate of 1.95%, supporting FDA approval.

Negatives

• Net loss for the three months ended September 30, 2025, increased by $4,818,000, or 61.1%, to $12,708,000.
• Net loss for the nine months ended September 30, 2025, increased by $14,194,000, or 62.2%, to $37,025,000.
• Selling and marketing expenses increased by $2,920,000, or 198.4%, for Q3 2025 and by $7,160,000, or 172.4%, for the nine months ended September 30, 2025, due to US commercial launch staffing.
• General and administrative expenses increased by $2,399,000, or 68.8%, for Q3 2025 and by $5,079,000, or 45.8%, for the nine months ended September 30, 2025, due to US expansion.
• Net cash used in operating activities increased by $10,640,000, or 70.4%, to $25,758,000 for the nine months ended September 30, 2025.
• Financial income decreased by $229,000, or 40.0%, for Q3 2025 and by $800,000 for the nine months ended September 30, 2025, due to lower interest rates and increased financial expenses from exchange rate changes.
• Accumulated deficit grew to $290,531,000 as of September 30, 2025, from $253,506,000 at December 31, 2024.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern for at least the next 12 months due to recurring losses and negative operating cash flows.
• The company needs to raise additional capital to meet future business requirements, and such capital raising may be costly, difficult to obtain, or could dilute stockholders' ownership interests.
• The company has only recently transitioned to a commercial stage in the United States, making it difficult to evaluate the success of its business and assess future viability.
• There is a risk that the commercial launch of CGuard Prime in the US may not achieve and sustain commercial success due to unpredictable timing of uptake and distribution efforts.
• The company faces challenges in recruiting and retaining adequate numbers of effective manufacturing, sales, and marketing personnel for its US expansion.
• Inability to price products at a sufficient point, difficulty obtaining reimbursement from payers, and lack of complementary products may put the company at a competitive disadvantage.
• Significant shifts in the political, economic, and military conditions in Israel and its neighbors could have a material adverse effect on business operations, as the company's manufacturing facility and key personnel are located in Israel.
• The company's commercial insurance does not cover losses from war and terrorism, and government coverage may not be maintained or sufficient.
• Changes to trade policy, including tariffs and customs regulations, or failure to comply with such regulations, may adversely affect the company's reputation, business, and financial condition, especially given reliance on Israeli manufacturing for the US market during transition.

Future Outlook

The company expects to continue incurring losses and negative cash flows from operations until its CGuard Prime product reaches commercial profitability. Management plans include continued commercialization of products and raising capital through equity sales, debt, strategic partnerships, and warrant exercises. The estimated addressable market for CGuard Carotid Stent System and SwitchGuard NPS is approximately $1.3 billion, with a total available market of $9.3 billion, which may grow with expanded treatment options. The company is also developing SwitchGuard NPS for transcarotid artery revascularization (TCAR) and exploring new indications for CGuard.

Management Comments

• "We expect to continue incurring losses and negative cash flows from operations until our product, CGuard EPS, reaches commercial profitability."
• "Managements plans include the continued commercialization of the Companys product and raising capital through the sale of additional equity securities, debt or capital inflows from strategic partnerships and exercise of warrants."

Industry Context

InspireMD's successful FDA approval and commercial launch of CGuard Prime in the US positions it to compete in the carotid artery stenting (CAS) market, which has expanded significantly due to CMS's broadened coverage for both asymptomatic and standard-risk patients. The company's focus on its proprietary MicroNet stent platform and development of a TCAR system (SwitchGuard NPS) aligns with industry trends towards less invasive procedures and improved embolic protection. The estimated multi-billion dollar addressable market indicates substantial growth potential, but the company faces intense competition from larger players with greater resources.

Comparison to Industry Standards

• The C-GUARDIANS trial demonstrated a 30-day DSMI rate of 0.95% for the CGuard Carotid Stent System, which compares favorably to the performance goal of <11.6% based on previous pivotal stent trials considered industry standard.
• One-year follow-up results from the C-GUARDIANS trial showed a combined rate of 30-day DSMI and ipsilateral stroke between 31 and 365 days of 1.95%, also indicating strong performance against historical benchmarks for carotid stenting.

Related Party Transactions

• A member of the immediate family of the CEO provided administrative services for the company's US expansion, totaling $8,000 for the three months ended September 30, 2025, and $56,000 for the nine months ended September 30, 2025. This engagement was terminated in July 2025.

Stakeholder Impact

• Shareholders face potential dilution from future capital raises and the risk associated with the 'going concern' warning.
• Employees and directors received significant grants of restricted shares and stock options, indicating continued investment in human capital.
• Customers in the US and international markets benefit from the commercial launch and continued adoption of the CGuard Prime carotid stent system.
• Creditors and investors face increased risk due to the company's recurring losses, negative cash flows, and the stated 'substantial doubt' about its ability to continue as a going concern.
• Suppliers may experience increased demand as the company scales up manufacturing and commercialization efforts, but also face the risk of the company's financial instability.

Next Steps

• Continue commercialization of the CGuard Prime carotid stent system in the United States.
• Continue to build out sales, marketing, and distribution capabilities in the US.
• Transfer manufacturing of CGuard Prime finished goods to Aptyx Interventional Systems' facility in North Carolina.
• Initiate the CGUARDIANS II pivotal study of the CGuard Prime 80cm Carotid Stent System for transcarotid revascularization (TCAR) procedures.
• Develop the SwitchGuard neuroprotection system (SwitchGuard NPS) for transcarotid access and neuro protection.
• Explore new indications for CGuard, such as acute stroke with tandem lesions.
• Raise additional capital through equity securities, debt, strategic partnerships, and warrant exercises to fund operations and address liquidity concerns.

Key Dates

Recommendation

While InspireMD achieved critical FDA approval and launched CGuard Prime in the US, driving significant revenue growth, the substantial increase in net losses and negative operating cash flow, coupled with the explicit 'going concern' warning, presents considerable financial risk. The recent capital raises provide a temporary buffer, but the long-term viability hinges on achieving commercial profitability, which remains uncertain. The stock is a 'hold' for investors who believe in the long-term potential of CGuard Prime and the company's ability to secure further financing and reach profitability, but it carries significant speculative risk due to its current financial state and the competitive landscape.

Keywords

InspireMD, NSPR, CGuard Prime, Carotid Stent System, Medical Device, FDA Approval, CE Mark, Q3 2025 Earnings, Financial Results, Going Concern, Capital Raise, Commercial Launch, Carotid Artery Disease, MicroNet, SwitchGuard NPS, TCAR, SEC Filing, 10-Q